Unlock stock picks and a broker-level newsfeed that powers Wall Street.
9.23
-1.23
(-11.76%)
At close: April 1 at 4:00:02 PM EDT
9.68
+0.45
+(4.88%)
After hours: April 1 at 6:01:44 PM EDT
Key Executives
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John G. Cox M.B.A. | CEO, President & Director | -- | -- | 1963 |
| Dr. Romesh Subramanian Ph.D. | Co-Founder & Advisor | 565.17k | -- | 1965 |
| Mr. Richard William Scalzo M.B.A. | Senior VP and Head of Finance & Administration | -- | -- | 1987 |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | 631.08k | -- | 1961 |
| Mr. Daniel Wilson | Senior VP & Head of Legal | -- | -- | 1972 |
| Ms. Lucia Celona | Chief Human Resource Officer | -- | -- | 1966 |
| Ms. Debra Feldman | Chief Regulatory Affairs Officer | -- | -- | 1971 |
| Dr. Ashish Dugar M.B.A., Ph.D. | Chief Medical Affairs Officer | -- | -- | -- |
| Ms. Johanna Friedl-Naderer | Chief Commercial Officer | -- | -- | 1968 |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer | -- | -- | 1967 |
Dyne Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 191
Description
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 30, 2025 at 8:00 PM UTC - May 5, 2025 at 8:00 PM UTC
Dyne Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
RNA Avidity Biosciences, Inc.
26.74
-9.42%
EWTX Edgewise Therapeutics, Inc.
20.13
-8.50%
WVE Wave Life Sciences Ltd.
7.74
-4.21%
STOK Stoke Therapeutics, Inc.
6.23
-6.32%
JANX Janux Therapeutics, Inc.
26.81
-0.70%
NAMS NewAmsterdam Pharma Company N.V.
18.38
-10.21%
ETNB 89bio, Inc.
6.80
-6.53%
BCYC Bicycle Therapeutics plc
7.85
-7.54%
SLDB Solid Biosciences Inc.
3.4450
-6.89%
CYTK Cytokinetics, Incorporated
37.50
-6.69%